- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
1. **Financial Highlights**: For Q3 FY25, Akums Drugs and Pharmaceuticals reported a total income of ₹10,250 Cr, slightly down from ₹10,918 Cr in Q3 FY24. Adjusted EBITDA rose to ₹1,359 Cr with a margin of 13.3%, up from 11.1% a year earlier. Adjusted PAT increased to ₹663 Cr, marking a 15% YoY growth. For the nine months of FY25, total income reached ₹30,972 Cr, while adjusted PAT was ₹1,903 Cr, reflecting an overall positive performance.
2. **Strategic Initiatives and Growth Drivers**: The company secured a €200 million contract to manufacture and supply products for European markets, which will significantly enhance its global footprint. Domestic operations saw a strong growth trajectory with new facilities contributing positively. Seven DGCI approvals were received in Q3, indicating progress in innovation and product development.
3. **Business Developments**: Akums has formed a partnership with Jagdale to expand its Ready-to-Drink product offerings and acquired exclusive rights to develop and market innovative products from Triple Hair and Caregen for the Indian market.
4. **Market Position and Competitive Advantage**: Akums holds a leading position in the Indian CDMO space, serving major players in various pharmaceutical segments. The company's robust infrastructure and diverse product offerings provide a competitive advantage in both domestic and international markets.
5. **Investor Implications**: The secured contracts and strong growth indicators coupled with strategic expansions present a positive outlook for investors. Watch closely as Akums aims to leverage its innovations and partnerships to sustain growth momentum in the upcoming fiscal periods.
All announcements from Akums Drugs and Pharmaceuticals Limited